论文部分内容阅读
目的：用大于常规剂量的异环磷酰胺（ IFO）、米托蒽醌（ MIT）、足叶乙甙（ Vp 16）联合治疗复发与难治性非霍奇金氏淋巴瘤 (non Hodgkin′ s lymphoma,NHL)，观察疗效及毒性。方法： 35例中、高度恶性 NHL，中位年龄 46岁， 6例难治性， 29例 2次以上复发。治疗方案： IFO 1.5 g/m2、 Vp 16 150 mg/m2静滴， d1～ 5； MIT 8 mg/m2静注， d1。同时用 G CSF或 GM CSF 75～ 150μ g/d，皮下注射，连用 7～ 14天。结果：总缓解率 71.4％（ 11例 CR， 14例 PR）。缓解期 3～ 35月，中位缓解期 24月。毒性反应主要是骨髓抑制， 大多数为Ⅰ、Ⅱ度。 结论： 71.4％的总缓解率可能得益于剂量的增加和造血因子的支持。 VIM方案治疗复发与难治性 NHL较安全有效。
OBJECTIVE: To treat recurrence and refractory non-Hodgkin’s lymphoma (IFM), mitoxantrone (MIT) and etoposide (Vp-16) in combination with conventional non-Hodgkin’s lymphoma ’S lymphoma, NHL), to observe the efficacy and toxicity. Methods: 35 cases of high grade NHL, median age 46 years, 6 cases refractory, 29 cases more than 2 times recurrence. Treatment options: IFO 1.5 g / m2, Vp 16 150 mg / m2 intravenous infusion, d1 ~ 5; MIT 8 mg / m2 intravenous, d1. At the same time with G CSF or GM CSF 75 ~ 150μ g / d, subcutaneous injection, once every 7 to 14 days. Results: The overall response rate was 71.4% (11 CR, 14 PR). The remission period of 3 to 35 months, the median remission in 24 months. Toxicity is mainly myelosuppression, most of Ⅰ, Ⅱ degrees. Conclusion: The overall response rate of 71.4% may be due to the dose increase and hematopoietic factor support. VIM regimen for the treatment of relapsed and refractory NHL is safe and effective.